Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: "Accusations about the responsible party behind the United States’ struggle to accelerate coronavirus testing have come from every which way and the blame has fallen, often inaccurately, on the shoulders of different public officials. In a March 13 tweet, President Donald Trump said the Centers for Disease Control and Prevention studied its testing system for decades but wasn’t prepared for a large scale pandemic, an issue that was complicated by policy changes made by former President Barack Obama. U.S. Sen. Chuck Schumer, D-N.Y., retweeted Trump’s remark and added his own comment: ""Trump is once again trying to blame the previous administration for the number of tests available. This is his #DailyLie."" U.S. Rep. Dan Crenshaw, R-Houston, retweeted Schumer’s remark and said: ""It’s not Obama’s fault and it’s not Trump’s fault. We have stringent FDA regulations, long in place, that created barriers to the private industry creating a test quickly."" PolitiFact looked at a different Trump claim blaming Obama for a lack of testing. We also looked at a claim from Democrat Joe Biden about the Trump administration rejecting tests from the World Health Organization (they were never offered). Trump also inaccurately stated that any individual who wants to be tested for the coronavirus can get a test. We wanted to dig deeper into Crenshaw’s claim, which attributes the delays in the availability of widespread testing to Food and Drug Administration regulations. Justin Discigil, spokesman for Crenshaw, pointed to articles from ProPublica, the New Yorker, The Atlantic and the Washington Post, all of which highlighted the role FDA regulations played here. He added: ""Just to be clear – nowhere did we say that these regulations were the sole/only reason for the testing issue, we said that they created barriers."" A timeline of events The first confirmed case of COVID-19 in the United States came at the end of January, when a man in Washington state developed symptoms after returning from a trip to Wuhan. One month later, federal health officials at the Centers for Disease Control and Prevention said it was inevitable that the U.S. would experience a spread of the virus and urged people to take precautions. In these early days of the virus, tests were not widely distributed to local and state laboratories. Instead, testing for the new coronavirus was conducted almost entirely by the CDC — samples collected at the local level were sent to the agency. Initial test kits developed by the CDC for use in local and state labs were flawed and produced inaccurate results in some labs, meaning they couldn’t be distributed. As the agency worked to correct the tests, health officials turned to the FDA. The U.S. Association of Public Health Laboratories submitted a letter asking the agency to use ""enforcement discretion"" and authorize local and state labs to develop and use their own tests. During a public health emergency, labs and drug manufacturers must seek an Emergency Use Authorization from the FDA to use diagnostic tests and medical treatments that have not gone through the typical clearance process — to share them faster in the emergency. (These authorizations were begun in 2004 under President George W. Bush.) For laboratory-developed tests, like the ones in question, FDA policy has stated that they cannot be used in clinical diagnoses without the FDA’s approval during an emergency. Although the goal of these regulations is to ensure only accurate lab tests are conducted, health officials have said they prevented them from quickly responding to the virus. One doctor in a Seattle lab described the process for getting an Emergency Use Authorization from the FDA and said the agency asked for a level of testing that didn’t make sense in the context of an emergency, according to a GQ profile. A doctor in North Carolina told NBC News that she had developed a test using the World Health Organization’s protocol but had yet to receive the use authorization from the FDA, putting the state ""way behind"" in its ability to test patients. On Feb. 29, the FDA announced a change in the process: Labs would still need to seek the agency’s approval for their tests, but the labs could begin testing while waiting for the official green light. On March 16, (three days after Crenshaw made his claim) the FDA announced another change to its policies and put state officials in charge of coronavirus tests developed by laboratories in their states, meaning labs would engage with state officials and not the FDA. It also removes the requirement for these labs to apply for an Emergency Use Authorization for their tests. The changes also expand which labs and manufacturers are included in FDA guidelines and which kinds of tests can be developed. ""We believe the unprecedented policy set forth in today’s updated guidance, which addresses laboratories and commercial manufacturers, will help address these urgent public health concerns by helping to expand the number and variety of diagnostic tests, as well as available testing capabilities in health care settings, and reference and commercial laboratories,"" reads a release from the agency. After the changes After the FDA announced changes to its policies, Labcorps and Quest Diagnostics both announced plans to start testing for the new coronavirus, crediting changes in federal policy with their ability to do so. ""We applaud the FDA for providing the flexibility for innovative, quality lab developed tests to be brought to patients and providers quickly to advance effective response to the coronavirus outbreak,"" said Steve Rusckowski, chairman and chief executive officer of Quest Diagnostics, in a statement. But even as state and local authorities move to ramp up testing, the number of available tests is still lacking. In Austin, for example, there is still a gap between available test kids and demand for testing, as officials prioritize testing for health care workers, people living in nursing homes and people at high risk for complications from the virus. Our Ruling Crenshaw said in a tweet that longstanding FDA regulations ""created barriers to the private industry creating a test quickly"" for the coronavirus. Crenshaw’s statement is accurate. FDA procedures adopted in 2004 meant laboratories had to seek the agency’s approval before developing and using tests in communities, a policy many health care officials have said prevented the country from taking early action in response to the novel coronavirus. It is important to keep in mind that other factors have contributed to the low levels of testing for the virus, beyond the FDA regulations. But Crenshaw’s statement is accurate." Claim: Dan Crenshaw Says longstanding Food and Drug Administration regulations “created barriers to the private industry creating a test quickly” for the coronavirus.

Output: Food and Drug Administration regulations in place since 2004 require labaratories to get an Emergency Use Authorization from the agency to use diagnostic tests and medical treatments that haven't gone through the typical clearance process. The policy was intended to speed up the process, but researchers reported significant delays between seeking an application and getting approval and these regulations played a role in that. The FDA has since changed the regulations to allow labs to start utilizing tests before receiving clearance.


Input: Consider Input: Paragraph: According to two studies published on Wednesday, DNA from these pre-modern humans may play a role in the appearance of hair and skin as well as the risk of certain diseases. Although Neanderthals became extinct 28,000 years ago in Europe, as much as one-fifth of their DNA has survived in human genomes due to interbreeding tens of thousands of years ago, one of the studies found, although any one individual has only about 2 percent of caveman DNA. “The 2 percent of your Neanderthal DNA might be different than my 2 percent of Neanderthal DNA, and it’s found at different places in the genome,” said geneticist Joshua Akey, who led one of the studies. Put it all together in a study of hundreds of people, and “you can recover a substantial proportion of the Neanderthal genome.”  Both studies confirmed earlier findings that the genomes of east Asians harbor more Neanderthal DNA than those of Europeans. This could be 21 percent more, according to an analysis by Akey and Benjamin Vernot, published online in the journal Science. Still, “more” is a relative term. According to the paper by geneticists at Harvard Medical School, published in Nature, about 1.4 percent of the genomes of Han Chinese in Beijing and south China, as well as Japanese in Tokyo come from Neanderthals, compared to 1.1 percent of the genomes of Europeans. Anthropologists expressed caution about the findings. Fewer than half a dozen Neanderthal fossils have yielded genetic material, said Erik Trinkaus of Washington University in  St. Louis, one of the world’s leading experts on early humans. Using this small sample to infer how much Neanderthal DNA persists in today’s genome is therefore questionable, he said. As expected, since Neanderthals never existed in Africa, Africans and those who trace their ancestry to that continent have almost no Neanderthal DNA, the Harvard team found. Human ancestors began migrating out of humanity’s natal continent as early as 1 million years ago, paleoanthropologists infer from fossil evidence, and between 500,000 and 200,000 years ago evolved into the robust, large-browed Homo neanderthalensis in Western Europe. Ever since scientists extracted DNA from the remains of Neanderthals, they have known that people today carry snippets of cavemen genes, in the amounts of 2 percent to 3 percent. That clinched the case that Neanderthals and modern humans interbred, probably 40,000 to 80,000 years ago, soon after the latter arrived in Europe from Africa. The new studies add details about how much DNA and of what kind we inherited. “The story of early human evolution is captivating in itself, yet it also has far-reaching implications for understanding the organization of the modern human genome,” Irene Eckstrand of the National Institutes of Health’s National Institute of General Medical Sciences, which partially funded the research, said in a statement. “Every piece of this story that we uncover tells us more about our ancestors’ genetic contributions to modern human health and disease.”  The Harvard team used a novel genetic algorithm to estimate the probability that a particular genetic variant arose from Neanderthals. Basically, they started with the genome of a 50,000-year-old Neanderthal, and determined whether pieces of it also appeared in some non-Africans but not in sub-Saharan Africans. The algorithm identified remnants of Neanderthal DNA, called alleles, in genes associated with type 2 diabetes, Crohn’s disease, lupus, biliary cirrhosis and smoking behavior. “But we can’t tell if the Neanderthal alleles are contributing to disease,” said Harvard’s Sriram Sankararaman, lead author of the paper in Nature. Areas “with increased Neanderthal ancestry tend to be higher the farther away you go from genes,” sitting, instead, in regions of the genome that do not actually produce the proteins, enzymes and other working molecules of the body. Neanderthal DNA does sit within some genes, however, such as those for keratin, a fibrous protein that makes skin, hair and nails tough and can be beneficial in colder environments by providing thicker insulation. The endurance of this Neanderthal DNA suggests that our caveman inheritance was adaptive, picked by natural selection to persist in our genome, generation after generation, because it conferred a survival advantage in individuals who carried it. The Harvard team analyzed the genomes of 1,004 people to estimate which populations got more or fewer Neanderthal DNA. Confirming a 2013 study, they found more in the genomes of east Asians than in Europeans. But they also dug deeper. Puerto Ricans and Spaniards have the least Neanderthal DNA, 1.05 percent and 1.07 percent respectively. That is curious because Neanderthals made their last stand on the Iberian peninsula, finally dying out there 28,000 years ago. Across all populations, Neanderthal DNA is conspicuously low in regions of the X chromosome and in testes-specific genes. The paucity of Neanderthal genes among those active in the testes suggests that interbreeding wasn’t a resounding success: It produced viable children, but the males were infertile. Although as much as 20 percent of Neanderthal DNA persists in modern genomes, according to the Washington scientists, vast regions of the latter are Neanderthal deserts. Among them is a region of chromosome 7 that includes a gene called FOXP2. “FOXP2 has previously been implicated in speech and language and may be an example of a gene that influences a uniquely human trait, which is why we find no Neanderthal sequences in these regions,” said Akey. Claim: Modern humans more Neanderthal than once thought, studies suggest.

Output: It’s getting harder and harder to take umbrage if someone calls you a Neanderthal.


Input: Consider Input: Paragraph: CES is allowing space for sex tech companies as a one-year trial. At the show, such companies were scattered throughout the health and wellness section, near startups pitching fitness trackers and infrared saunas. Lora DiCarlo, a startup that pushed for changes after organizers revoked its award, showed off its Osé robotic “personal massager.” It’s one of a dozen companies at the show focused on vibrators, lube dispensers and other sex tech products. Founders of these startups say their products are about empowerment and wellness for women, something they say has often been overlooked in tech. The historically male-dominated tech trade show has received criticism in past years for having an all-male lineup of speakers and for previously allowing scantily clad “booth babes,” fostering a “boys’ club” reputation. Besides allowing sex tech, CES organizers brought in an official “equality partner,” The Female Quotient, to help ensure gender diversity. The Female Quotient, which trains companies in equality practices, will hold a conference for women during the four-day show, which opened Tuesday. “It’s been a process,” said Gary Shapiro, the head of the Consumer Technology Association, which puts on CES. It’s been a longer process for many sex tech companies to convince investors that they are part of a growing trend that has enough customers. Much of the push has come from the startups’ female founders and from younger consumers who talk more openly about sexuality. As with other technologies, some exhibitors including Lora DiCarlo had prominent booths at CES, while others such as the wearable vibrator company Crave were tucked away. Crave’s exhibit included a camper with a “Build-a-Vibe-Workshop,” where attendees could get an engraved vibrator to wear around their neck. Sex tech has existed in some form for decades. But the gates really began to open in 2016, said Andrea Barrica, founder of sex education site O.school. That year, several other “fem tech” companies made progress in areas such as menstruation and menopause. Those paved the way for sex tech to grow and get investors interested. “Larger institutions are starting to take note, all the way from VC firms to large Fortune 100 companies,” said Barrica, who recently published the book “Sextech Revolution: The Future of Sexual Wellness.” Large institutions like CES had no choice but to look at sex tech, she said. The journey hasn’t been easy. Sex tech founders, many of them women, recount being turned down by dozens of investors. They faced decency arguments and entrenched corporate standards that equated them with porn. But investors are becoming more receptive, said Cindy Gallop, a former advertising executive turned sex tech entrepreneur and founder of the website MakeLoveNotPorn. “It’s entirely because of our refusal to allow the business world to put us down,” she said. Founders insist that their devices — ranging from vibrators to lube dispensers to accessories — have effects outside the bedroom. “Sexual health and wellness is health and wellness,” said Lora DiCarlo, CEO and founder of the company of the same name. “It does way more than just pleasure. It’s immediately connected to stress relief, to better sleep, to empowerment and confidence.” DiCarlo’s $290 Osé device has gotten $3 million worth of advance sales, bolstered in part by the attention it received after CES organizers overturned a decision by an independent panel of judges to give the vibrator a prestigious Innovation Honoree Award in the robotics and drone category. The organizers, CTA, told the company it reserved the right to rescind awards for devices deemed “immoral, obscene, indecent, profane or not in keeping with CTA’s image.” DiCarlo and other female founders pushed back for banning them but allowing humanoid sex robots meant to serve men the previous year. Following criticism, CES organizers ultimately  reinstated the award and apologized. A few months later, the show announced policy changes such as a dress code to prevent skimpy outfits and new “Innovation for All” sessions with senior diversity officials. Osé began shipping to customers this month. DiCarlo said the company is planning to introduce new devices, including less expensive options. Sex tech companies still face major barriers to growth. Polly Rodriguez, CEO of sexual wellness company Unbound, said the company is profitable and customers are more open about buying products than they once were. But she said she still faces roadblocks advertising on social media, and many traditional investors snub the company. “Things are better, but there’s just still this genuine fear of female sexuality more broadly within the institutional side of technology,” she said. And while Gallop offered to speak at CES, conference organizers declined, saying sex tech was not a part of its conference programming. ___ AP Business Writer Joseph Pisani contributed to this report. ___ AP’s CES coverage: https://apnews.com/Consumerelectronics Claim: Sex tech from women-led startups pops up at CES gadget show.


Output: Sex tech is gracing the CES gadget show in Las Vegas this week, a year after organizers took fire for revoking an innovation award to a sex device company led by a female founder.